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RESEARCH ARTICLE
The Menkes and Wilson disease genes counteract in copper
toxicosis in Labrador retrievers: a new canine model for
copper-metabolism disorders
Hille Fieten1,*, Yadvinder Gill2, Alan J. Martin2, Mafalda Concilli3, Karen Dirksen1, Frank G. van Steenbeek1,
Bart Spee1, Ted S. G. A. M. van den Ingh4, Ellen C. C. P. Martens1, Paola Festa3, Giancarlo Chesi3,
Bart van de Sluis5, Roderick H. J. H. Houwen6, Adrian L. Watson2, Yurii S. Aulchenko7,8,
Victoria L. Hodgkinson9,10, Sha Zhu9,10, Michael J. Petris9,10,11, Roman S. Polishchuk3,
Peter A. J. Leegwater1 and Jan Rothuizen1
ABSTRACT
The deleterious effects of a disrupted copper metabolism are
illustrated by hereditary diseases caused by mutations in the genes
coding for the copper transporters ATP7A and ATP7B. Menkes
disease, involving ATP7A, is a fatal neurodegenerative disorder of
copper deficiency. Mutations in ATP7B lead to Wilson disease, which
is characterized by a predominantly hepatic copper accumulation.
The low incidence and the phenotypic variability of human copper
toxicosis hamper identification of causal genes or modifier genes
involved in the disease pathogenesis. The Labrador retriever was
recently characterized as a new canine model for copper toxicosis.
Purebred dogs have reduced genetic variability, which facilitates
identification of genes involved in complex heritable traits that might
influence phenotype in both humans and dogs. We performed a
genome-wide association study in 235 Labrador retrievers and
identified two chromosome regions containing ATP7A and ATP7B
that were associated with variation in hepatic copper levels. DNA
sequence analysis identified missense mutations in each gene. The
amino acid substitution ATP7B:p.Arg1453Gln was associated with
copper accumulation, whereas the amino acid substitution ATP7A:p.
Thr327Ile partly protected against copper accumulation. Confocal
microscopy indicated that aberrant copper metabolism upon
expression of the ATP7B variant occurred because of mis-
localization of the protein in the endoplasmic reticulum. Dermal
fibroblasts derived from ATP7A:p.Thr327Ile dogs showed copper
accumulation and delayed excretion. We identified the Labrador
retriever as the first natural, non-rodent model for ATP7B-associated
copper toxicosis. Attenuation of copper accumulation by the ATP7A
mutation sheds an interesting light on the interplay of copper
transporters in body copper homeostasis and warrants a thorough
investigation of ATP7A as a modifier gene in copper-metabolism
disorders. The identification of two new functional variants in ATP7A
and ATP7B contributes to the biological understanding of protein
function, with relevance for future development of therapy.
KEY WORDS: ATP7A, ATP7B, Dog, Liver
INTRODUCTION
Copper is an essential trace element for a wide range of biochemical
processes in the body. The P-type copper-transporting ATPases
ATP7A (Vulpe et al., 1993) and ATP7B (Bull et al., 1993) are
crucial for copper homeostasis. At the cellular level, these proteins
have a biosynthetic role in the trans-Golgi network, where they
facilitate incorporation of copper into proteins. Furthermore, they
prevent toxic accumulation of cellular copper by redistribution to a
vesicular compartment, resulting in excretion of copper through
either the apical membrane (ATP7B) or the basolateral membrane
(ATP7A). This redistribution involves metal-binding domains
(MBDs) in cytoplasmic domains of the proteins and is regulated
in part by their phosphorylation state (Voskoboinik et al., 2002).
Body copper homeostasis is maintained by balancing the rates of
dietary copper absorption and biliary copper excretion. ATP7A is
highly expressed in enterocytes, where it is involved in copper uptake
across the basolateral membrane into the portal circulation for delivery
to the liver, where copper is stored (Linder and Hazegh-Azam, 1996).
Besides its function in intestinal epithelial cells, ATP7Awas recently
identified to play an important role in hepatic copper mobilization in
response to copper demands of peripheral tissues (Kim et al., 2010).
Excess hepatic copper is excreted into the bile and requires expression
of functional ATP7B in hepatocytes (Gitlin, 2003).
The severe effects of copper-metabolism imbalance are illustrated
by inherited disorders resulting frommutations in ATP7A and ATP7B.
Mutations in ATP7A result in a fatal, X-linked copper-deficiency
disorder in infants known as Menkes disease. The disease is
characterized by cerebral and cerebellar degeneration, failure to
thrive, coarse hair and connective tissue abnormalities (Kaler, 2011).
Wilson disease results from mutations in ATP7B (Gitlin, 2003)
and is associated with copper accumulation in the liver and
secondarily in the brain, resulting in hepatic cirrhosis and neuronal
degeneration. The age of onset and the clinical manifestations vary
greatly between individuals affected byWilson disease. This lack ofReceived 30 January 2015; Accepted 27 October 2015
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genotype-phenotype correlation might be influenced by currently
unidentified genetic modifiers. Other hereditary diseases leading to
hepatic copper accumulation in infants include Indian childhood
cirrhosis (Tanner, 1998) and endemic Tyrolean infantile cirrhosis
(Müller et al., 1996). In these diseases, the causal genes are currently
unknown, and dietary copper intake is believed to contribute
significantly to disease progression.
In order to develop new treatment strategies for copper-metabolism
disorders, several rodent models were investigated, including natural
models, such as the mottled mouse (Grimes et al., 1997), the toxic
milk mouse (Theophilos et al., 1996) and the Long–Evans cinnamon
rat (Li et al., 1991), in addition to ATP7A (Wang et al., 2012) and
ATP7B knockouts (Buiakova et al., 1999). Although rodent models
are invaluable for studying diseases, the dog as a large-animal model
represents a unique translational bridge between rodents and humans.
The best-characterized canine model for copper toxicosis is the
Bedlington terrier, in which severe hepatic copper accumulation is
caused by a deletion in the COMMD1 gene (Van de Sluis et al.,
2002). However, convincing evidence of involvement of the
COMMD1 gene in human copper-metabolism disorders is lacking
(Coronado et al., 2005; Lovicu et al., 2006; Müller et al., 2003).
The Labrador retriever dog breed was recently characterized as a
newmammalianmodel for copper toxicosis, distinct fromCOMMD1-
associated autosomal recessive copper toxicosis. In predisposed
Labrador retrievers, hepatic copper accumulation induces hepatic
cirrhosis, usually inmiddle-aged dogs. Female Labrador retrievers are
at increased risk for the disease (Fieten et al., 2012b).
The genes underlying the disease in Labrador retrievers were not
known. We hypothesized that identification of these genes would
contribute to the understanding of copper-metabolism biology in
dogs and other mammals. Given that the copper genome is highly
conserved across species, this study might reveal genes that are
candidate modifiers in human copper-metabolism disorders.
Furthermore, elucidating the genetic background of copper
toxicosis in Labrador retrievers contributes to the characterization
of this new model for copper-metabolism disorders, necessary to
exploit its possibilities fully.
Whereas gene-mapping studies in human complex diseases
require thousands of affected individuals and millions of single
nucleotide polymorphism (SNP) markers, smaller numbers suffice
for a genome-wide association study (GWAS) of inbred pedigree
dogs owing to the reduced genetic and phenotypic heterogeneity.
Therefore, the dog is a useful model for identifying genes in
naturally occurring complex hereditary diseases that are
phenotypically similar in dogs and humans (Boyko, 2011).
The aims of the present study were to identify gene variants
involved in copper toxicosis in the Labrador retriever and to provide
biological evidence for their involvement in the disease.
RESULTS
Dogs
The initial GWAS cohort consisted of 235 Labrador retrievers. The
independent replication cohort consisted of 59 Labrador retrievers.
The median copper score in the 294 Labrador retrievers included in
the study was 1.5 (range 0-5). A summary of characteristics of the
dogs, including age, sex and hepatic copper scores, is provided in
Table S1.
Electron microscopic evaluation of copper toxicosis in
Labrador retrievers
To complement the phenotype description of copper toxicosis in
Labrador retrievers, liver biopsies of two Labrador retrievers
affected with copper toxicosis and a control were assessed by
electron microscopy. Ultrastructural changes in the biopsies of the
affected dogs corresponded to copper-laden lysosomes, comparable
to what is recognized by electron microscopy of the liver of human
individuals with Wilson’s disease (Fig. 1).
Genome-wide association study of copper toxicosis in
Labrador retrievers
After quality control of genotype data used for the GWAS, 35.7% of
SNPs were removed because of a low minor allele frequency and
0.7% of SNPs had a call rate of less than 98%, leaving 109,496 SNPs
and 235 dogs for analysis. Population stratification was determined
by a multidimensional scaling plot (Fig. S1), and inflation of the test
statistic was inspected by a QQ-plot (Fig. S2). The heritability of
hepatic copper score was estimated to be 0.48. The highest
association signal using hepatic copper level as a quantitative trait
in a linear mixed model was identified on chromosome 22, with a
P-value of 2.4×10−6 and a β of 0.65 (s.e. 0.14; Fig. 2A). Inspection of
the region showed a linkage disequilibrium (LD) block at the first
10 Mb of the chromosome. The crucial interval was determined to be
at 22:152034-10753911, which contained 83 genes, including
the candidate gene ATP7B, located at position 22:162769-225266
(Canfam 3.1; Fig. 2B).
A stratified analysis for males and females was performed
(Fig. 2C,D). In the male subset, the crucial region was located at
X:54322875-65713151 and contained 77 genes. The highest
association signal [P=1.1×10−4 and a β of −0.57 (s.e. 0.15)] was
caused by six SNPs that formed an LD block of 8.2 Mb, including
the candidate gene ATP7A at position X:60203319-60356690
(Fig. 2C).
Given the fact that ATP7A and ATP7B code for copper
transporters, they were strong candidate genes for involvement in
copper toxicosis; therefore, we focused on these genes for in-depth
DNA sequence analysis. A list of observed DNA variants and their
effect on the hepatic copper score is presented in Table 1.
The five nominally significant variations (P≤0.05)were genotyped
in an independent cohort of 59 Labrador retrievers (Table 1;
Table S1). The association with hepatic copper score was replicated
for the non-synonymous nucleotide substitution of ATP7A at X-
chromosomal position 60279238 (ENSCAFT00000049745 ATP7A:
c.980C>T), the intronic variation in ATP7A (position X:60338569)
and the non-synonymous nucleotide substitution of ATP7B at
chromosome 22, position 225112 (ENSCAFT00000006859
ATP7B:c.4358G>A). When analysed in the complete data set
(n=294), the P-values were similar to or lower than initially derived
in the GWAS; 1.6×10−4 and 4.9×10−7 for ATP7A:c.980C>T and
ATP7B:c.4358G>A, respectively (Table 1).
When inspecting the effect of the combined genotypes for ATP7A
and ATP7B on hepatic histological copper levels (Table 2), we
appreciated that for both sexes ATP7B:c.4358Awas associated with
increased hepatic copper levels in an additive way. This effect is
most clear in female dogs, leading to a significant difference
between copper levels of dogs homozygous for ATP7B:c.4358A
and any of the other dogs. Concurrent presence of ATP7A:c.980T
attenuated the copper accumulation effect in both sexes. This effect
was most notable in males, leading to a significant difference
between dogs with and without the mutant allele of ATP7A
(Table 2).
The heritability for hepatic copper score in the model including
the co-variates sex, ATP7A:c.980C>T and ATP7B:c.4358G>A was
calculated to be 0.42. Thus, the explained genetic variability by the
two non-synonymous mutations is [(0.48−0.42)/0.48] 12.5%, of
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which 4.3% could be attributed to ATP7A:c.980C>T and 8.2%
could be attributed to ATP7B:c.4358G>A.
ATP7A:c.980C>T resulted in an amino acid substitution from a
threonine to an isoleucine in the thirdMBD of ATP7A at position 327
(Ensembl: ENSCAFT00000049745, ATP7A:p.Thr327Ile). ATP7B:
c.4358G>A caused an amino acid substitution from an arginine to a
glutamine in the C-terminus of the ATP7B protein at position 1453
(Ensembl: ENSCAFT00000006859, ATP7B:p.Arg1453Gln).
Alignment of the amino acid sequence adjacent to canine ATP7A:p.
Thr327Ile (ATP7AT327I) and ATP7B:p.Arg1453Gln (ATP7BR1453Q)
indicated strong conservation of the domains inmammals (Fig. 3A,B).
Functional evaluation of ATP7BR1415Q
ATP7BR1415Q is partly mis-localized to the endoplasmic reticulum
To analyse how the canine ATP7B:p.Arg1453Gln might affect
copper homeostasis at the cellular level, we expressed the mutant
protein exogenously in a cell line. To investigate the consequences
of canine ATP7B:p.Arg1453Gln substitution on the subcellular
localization of ATP7B, the conserved arginine (Arg) at position 1415
(Ensembl: ENST00000242839) of human GFP-tagged ATP7B was
replaced by a glutamine (Gln). Both humanATP7B:p.Arg1415-GFP
(ATP7BWT) and ATP7B:Gln1415-GFP (ATP7BR1415Q) were
expressed in HeLa cells and and treated with either bathocuproine
disulphonate (BCS) or 200 μM CuSO4. Confocal microscopy
revealed that in low-Cu2+ conditions, ATP7BWT-GFP exhibited
significant overlap with the trans-Golgi marker TGN46 as reported
before (Barnes et al., 2009),whereas stimulationwithCuSO4 induced
ATP7BWT-GFP trafficking to the cell surface andnumerous cytosolic
vesicular structures (Fig. 4A; Fig. S3). In contrast, a significant
amount of ATP7BR1415Q-GFP was detected in the endoplasmic
reticulum (ER) network-like membranes in both low- and high-Cu2+
conditions (Fig. 4A; Fig. S3), although substantial amounts of the
protein were delivered to the Golgi and post-Golgi compartments.
Morphometric analysis confirmed an increase in the percentage of
cells that exhibited GFP signal in the ER upon expression of
ATP7BR1415Q, whereas the number of cells with ATP7BWT-GFP in
the ER was very low (Fig. 4C). Partial mis-localization of
ATP7BR1415Q to the ER compartment was also observed in an
HepG2 cell line (Fig. 4B,C). This indicated that the substitution of
arginine to glutamine impairs (at least partly) appropriate
compartmentalization of ATP7B.
ATP7BR1415Q fails to reach the canalicular domain of polarized HepG2
cells
To verify whether ATP7BR1415Q can be targeted to the apical
(canalicular) domain of hepatic cells, which is necessary to remove
Fig. 1. Hepatic ultrastructure in Labrador retrievers with elevated
copper levels. (A,B) Low (A) and high (B) magnification of thin
sections from the liver reveal regular organization of the hepatic
tissue in a 1-year-old male cross-breed (control dog, hepatic copper
250 mg/kg dwl). (C,D) Ultrastructure of an 11-year-old female
Labrador retriever [affected dog, hepatic copper 756 mg/kg dry weight
liver (dwl)] exhibits wide areas with accumulation of electron-dense
material (C, arrows), which at higher magnification appear as copper-
laden lysosomes comparable to what is observed in humans with
Wilson disease (D, arrows). (E,F) Ultrastructure of a liver biopsy of a
12-year-old female Labrador retriever (affected dog, hepatic copper
1445 mg/kg dwl); some areas of the liver show severe disorganization
of the tissue architecture (E), with massive electron-dense inclusions
(E,F; arrows). Arrowheads in F indicate bundles of collagen fibres as a
sign of extensive fibrosis.
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excess Cu2+ from hepatocytes into bile, we grew HepG2 cells in the
conditions that allow their maximal polarization (Slimane et al.,
2003). Then, the cells were transfected with either ATP7BWT-GFP
or ATP7BR1415Q-GFP and subsequently incubated with 200 μM
CuSO4. Stimulation with copper resulted in delivery of ATP7B
WT-
GFP to the apical surface domains, which was labelled with the
canalicular marker multidrug resistance protein 2 (MRP2) (Fig. 4B;
Fig. S4). On the contrary, ATP7BR1415Q-GFP failed to arrive at the
canalicular surface of the cells (Fig. 4B; Fig. S4) and remained
mainly in the intracellular cytoplasmic structures, as it has
been already demonstrated for another ER-retained mutant,
ATP7BH1069Q (Polishchuk et al., 2014). These results indicated
that the mutant cannot be delivered efficiently to regular copper-
excretion sites in polarized hepatocytes.
ATP7BR1415Q exhibits copper-transporting activity
To assess the ability of ATP7BR1415Q to transport copper, we
transfected HeLa cells with the metal-responsive element (MRE)-
luciferase reporter, a copper sensor based on the metallothionein-1
promoter that responds to bioavailable cytosolic copper and that
was previously used to characterize cellular copper import (van
den Berghe et al., 2007). Co-expression of MRE-luciferase
reporter with empty GFP vector resulted in strong induction of
luciferase activity (Fig. 4D) upon exposure of the cells to CuSO4.
The induction of this copper-dependent reporter was significantly
reduced when ATP7BWT was co-expressed in the cells, whereas
transfection of the partly active ATP7BH1069Q mutant resulted in
only modest inhibition of MRE-luciferase activation (Fig. 4D).
Cells expressing ATP7BR1415Q exhibited substantial reduction of
Fig. 2. Manhattan plots for hepatic copper score in
Labrador retrievers. (A) Manhattan plot of hepatic copper
score in 235 Labrador retrievers shows a genome-wide
association signal at chromosome 22. (B) Manhattan plot of
chromosome 22 shows that the signal comprises an LD
block comprising the first 10 Mb of the chromosome. The
arrow indicates the location of ATP7B. (C) Mapping results
for hepatic copper score at the X chromosome in male dogs
shows an association signal at position X:60203319-
60356690 (CanFam 3.1). The arrows indicate the location of
ATP7A. (D) Mapping results for hepatic copper score at the X
chromosome in females shows no substantial association.
Note that the solid line indicates the boundary for suggestive
genome-wide association at a significance level of
P=5×10−5. The dotted line indicates the boundary used for
determination of the crucial regions at P=5×10−4.
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reporter activity (Fig. 4D), while expressing a similar amount of
protein to ATP7BWT-transfected cells (Fig. S5). This observation
indicates that ATP7BR1415Q is still capable of transporting copper
out of the cytosol and that observed differences are not the result of
differences in protein expression.
Taken together, our findings indicate that accumulation of
copper upon ATP7BR1415Q expression occurs mainly as a result of
failure of the mutant to reach the appropriate copper-excretion
compartments rather than as a result of a reduction in its copper-
translocating activity.
Fig. 3. Protein domains of ATP7A and ATP7B involved in
copper toxicosis in Labrador retrievers.Overview of the ATP7A
(A) and ATP7B (B) proteins with the N-terminus, metal-binding
domains (MBDs), actuator domain (A), nucleotide-binding domain
(N), phosphorylation domain (P) and the C-terminus. The green
asterisk indicates the position of the mutations. (A) Alignment of
the region containing ATP7AT327I (in green) shows a strong
conservation of this amino acid position in the human, rat, mouse,
cow, cat and horse. The copper-binding site XMXCXXC (boxed),
predicted α-helix (red) and β-sheets (blue) are indicated.
(B) Alignment of the region containing ATP7BR1453Q (in green)
shows a strong conservation of this amino acid position in the
human, rat, mouse, cow, cat and horse. The predicted α-helix (red)
and β-sheets (blue) are indicated.
Table 2. Hepatic histological copper score in relation to ATP7A and ATP7B genotype in male and female Labrador retrievers
Males Females
ATP7A:c.980C>T genotypes




























Combinations of genotypes of individual dogs for ATP7A:c.980C>T and ATP7B:c.4358G>A are indicated. Data are presented for male dogs and female dogs
separately. The number of dogs (n) and median and range (in parentheses) for hepatic copper score per genotype category are summarized. Significant
differences between genotype categories are indicated by letters in males (a,b,c) and females (y,z). Genotypes for which fewer than five animals were present
were omitted from the statistical analysis.
30


















Canine dermal fibroblasts expressing ATP7AT327I accumulate more
copper than wild-type fibroblasts
To ascertain whether ATP7A:9.Thr327Ile (ATP7AT327I) influenced
cellular copper accumulation, a copper uptake and retention assay
(Moller et al., 2011) was performed using copper 64 isotope (64Cu)
in dermal fibroblasts.
Fibroblasts with ATP7AWT were derived from five female and
three male dogs, and fibroblasts with the variant ATP7AT327I were
Fig. 4. Functional evaluation of ATP7BR1415Q. (A) HeLa cells were transfected with either ATP7BWT or ATP7BR1415Q and either treated with 500 µM of the
copper chelator BCS (Cu−) or incubated for 2 h with 200 µM CuSO4 (Cu
+). In low-copper conditions, the localization of ATP7BWT overlapped with the trans-Golgi
marker TGN46, whereas copper stimulation induced ATP7BWT trafficking to cytosolic vesicular structures and the cell surface (upper row). A significant cohort of
ATP7BR1415Q was detected in the endoplasmic reticulum network-like membranes in both low- and high-copper conditions (lower row). White scale bars: 5 µm.
(B) Polarized HepG2 cells were exposed to BCS or CuSO4 for 4 h and stained with canalicular marker MRP2 and nuclear marker DAPI. White arrows indicate
canalicular vacuole (cyst), which does not contain either wild-type or mutant ATP7B in chelator-treated cells. In contrast, the canalicular vacuole receives
ATP7BWT upon Cu stimulation, whereas ATP7BR1415Q fails to reach the canalicular surface domain. White scale bars: 5 µm. (C) The intracellular distribution of
GFP-tagged ATP7BWT and ATP7BR1415Q protein was analysed in HeLa (lower graph) and HepG2 (upper graph) cells in low- and high-copper circumstances. The
number of cells used for quantification is indicated in parentheses. Significant differences (P<0.05) in the distribution of GFP within the cellular compartments are
indicated with a,b,c (ER), 1,2,3 (Golgi) or x,y,z (plasma membrane or vesicles). There was an increase in the percentage of cells that exhibited GFP signal in the
endoplasmic reticulum upon expression of ATP7BR1415Q-GFP, whereas the number of cells with ATP7BWT-GFP in the endoplasmic reticulumwas very low in both
HeLa and HepG2 cells. (D) HeLa cells were transfected with empty vector, ATP7BWT, ATP7BH1069Q or ATP7B R1415Q and the metal-responsive element (MRE)-
luciferase reporter for 24 h and treated with 200 μM CuSO4 for 24 h. Induction of the MRE-luciferase reporter was reduced when ATP7B
WT was co-expressed in
the cells, whereas transfection of the partly active ATP7BH1069Q mutant resulted in only modest inhibition of MRE-luciferase activation. Cells expressing
ATP7BR1415Q exhibited substantial reduction of reporter activity, indicating that ATP7BR1415Q is still capable of transporting copper away from the cytosol. Bars
represent the mean values of normalized luciferase activity (see Materials and Methods), and standard deviation is depicted by the error bars.
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derived from four female and three male dogs, and used for the 64Cu
experiments. For the 65Zinc experiments, fibroblasts from three
ATP7AWT dogs (two females, one male) and three ATP7AT327I
dogs (one female, two males) were used. All dogs used for the
fibroblast studies that were homo- or hemizygous for ATP7A:
c.980C were homo- or hemizygous for the reference allele for the
SNP in intron 18 (position 60338569), and all dogs that were homo-
or hemizygous for ATP7A:c.980T were homo- or hemizygous for
the non-reference allele.
The model for 64Cu accumulation in fibroblasts that included the
fixed factors time and mutation had the lowest Akaike’s information
criterion (AIC). Overall, a significant increase of copper at time points
22 and 30 hwas present. The fibroblasts derived from theATP7AT327I
dogs accumulated significantly more copper than fibroblasts derived
from ATP7AWT dogs (Fig. 5A).
To establish whether the differences in 64Cu levels between
fibroblasts were the result of abrogated efflux, a chase method was
used, after preloading of cells with copper for 22 h. The average
export rate of fibroblasts with the ATP7AT327I variant was
significantly lower compared with the average export rate in
fibroblasts derived from ATP7AWT (Fig. 5B). Western blots of
dermal fibroblasts derived from ATP7AWT and ATP7AT327I dogs
did not show differences in ATP7A protein expression (Fig. S6).
As a control, fibroblasts from a human fibroblast cell line
(ATP7AWT) and a human Menkes disease-affected individual
(Menkes; both n=1) were included in the experiments. Fibroblasts
derived from the human with Menkes disease accumulated
considerably more 64Cu than the ATP7AWT fibroblasts (Fig. 5C)
and showed abrogated efflux (Fig. 5D).
Handling of an alternative trace metal in canine fibroblasts was not
influenced by the ATP7A genotype. Incubation of fibroblasts with
65Zn resulted in similar patterns of accumulation of isotope over time
(Fig. S7A), and the release kinetics of newly accumulated 65Zn were
comparable between the fibroblasts derived fromATP7AWT dogs and
dogs with ATP7AT327I (Fig. S7B). In summary, this experiment
showed that fibroblasts derived from dogs with the ATP7AT327I
accumulate more copper than fibroblasts derived from dogs with
ATP7AWT and that copper accumulation might be the result of
decreased copper excretion by ATP7AT327I fibroblasts.
Copper-induced trafficking is not changed in cells expressing
ATP7AT327I
To investigate whether the observed decrease in copper excretion
was a result of aberrant trafficking, immunofluorescence studies
were performed in canine dermal fibroblasts derived from
ATP7AWT and ATP7AT327I dogs. Both variants reside in the
Fig. 5. Copper accumulation and retention
in canine dermal fibroblasts. (A) Copper
influx in canine fibroblasts. Dermal fibroblasts
derived from ATP7A:p.Ile327 (ATP7AT327I)
dogs showed significantly more uptake of
64Cu than dermal fibroblasts derived from
dogs with ATP7A:p.Thr327 (ATP7AWT). The
overall difference in copper accumulation
was 86% (95% confidence interval 25-176%,
P=6.1×10−3). The overall increase in 64Cu
was compared to time point 6 h. After 22 h,
the estimated increase in copper was 45%
(95% confidence interval 27-64%,
P<1.0×10−4), and after 30 h this was 72%
(95% confidence interval 45-104%,
P<1.0×10−4). Dots represent mean values,
and standard deviation is represented by the
error bars. (B) Copper efflux in canine
fibroblasts. Dermal fibroblasts from
ATP7AT327I dogs showed significantly more
retention of copper than dermal fibroblasts
derived from dogs with ATP7AWT. The overall
average export rate in ATP7AT327I was
significantly lower than in ATP7AWT
(P=0.011). Dots represent mean
percentages, and standard deviation is
represented by the error bars. (C) Copper
influx in human fibroblasts. Dermal
fibroblasts from a human with Menkes
disease showed considerably more uptake of
copper than dermal fibroblasts derived from a
human with ATP7A wild type. (D) Copper
efflux in human fibroblasts. Dermal
fibroblasts from a human with Menkes
disease showed considerably more retention
of copper than dermal fibroblasts derived
from a person with ATP7A wild type.
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Golgi in low-copper circumstances. After 2 h incubation with
copper, both ATP7AWT and ATP7AT327I exhibited substantial
redistribution from the Golgi to the small post-Golgi vesicles and
plasma membrane (Fig. S8).
To understand whether basolateral targeting of ATP7AT327I was
compromised, apicobasal distribution of both ATP7AWT and
ATP7AT327I was investigated in filter-grown polarized Madin–
Darby canine kidney (MDCK) cells. The MDCK cells were
transfected with GFP-tagged versions of either ATP7AWT or
ATP7AT327I and exposed to CuSO4 for 4 h. Confocal microscopy
revealed efficient delivery of ATP7AWT to the lateral cell surface
domain of MDCK located below the occludin-labelled belt of tight
junctions. As did the wild-type protein, ATP7AT327I exhibited
efficient targeting to the lateral walls of MDCK cells (Fig. S9),
indicating that its polarized delivery in epithelial cells remained
unaffected.
DISCUSSION
We performed a GWAS in 235 Labrador retrievers to identify causal
genes for copper toxicosis. We identified two chromosomal loci that
were positively and negatively associated with hepatic copper
levels. The two loci respectively harboured the genes coding for the
copper transporters ATP7B and ATP7A. Subsequent Sanger
sequencing in 96 Labrador retrievers and validation of mutations
in an independent cohort of 59 Labrador retrievers identified a non-
synonymous SNP in ATP7B associated with an increase in hepatic
copper levels, and a non-synonymous and intronic SNP in ATP7A
associated with a decrease in hepatic copper levels. Functional
follow-up studies for the non-synonymous mutations provided
biological evidence for their involvement in a disturbed copper
metabolism.
Copper toxicosis in Labrador retrievers and Wilson disease are
similar with regard to the amount of hepatic copper accumulation,
presence of iron accumulation and progression to liver cirrhosis.
Electron microscopy of liver sections of affected Labrador retrievers
revealed ultrastructural changes that are similar to those observed in
humans with Wilson disease. We show, for the first time, that
Labrador retrievers and humans with Wilson disease share ATP7B
as the causal gene. However, histopathological differences between
copper toxicosis in Labrador retrievers and Wilson disease are
present and include predominant centrolobular copper accumulation
in Labrador retrievers versus a periportal distribution in humans
with Wilson disease. Furthermore, fatty degeneration and Mallory
bodies are not recognized in liver histopathology from Labrador
retrievers. In both diseases, the age of onset is usually in middle or
older age, but neurological symptoms and Kaiser–Fleisher rings
have not been recognized in Labrador retrievers.
Dietary intake of copper seems important in disease progression
in Labrador retrievers (Fieten et al., 2014, 2012a) and, in this regard,
Labrador retriever copper toxicosis is comparable to endemic
Tyrolean infantile cirrhosis and Indian childhood cirrhosis. The
observed differences among copper toxicosis diseases in humans
and Labrador retrievers are intriguing, and further studies are
needed to identify whether they can be attributed to general species
differences in copper metabolism or to other, yet to be identified
gene mutations in either species.
ATP7B is highly expressed in hepatocytes, where it is located in
the trans-Golgi network in low-copper conditions. With increasing
intracellular copper levels, ATP7B traffics to endo-lysosomal
vesicular structures and to the canalicular surface of hepatocytes
(Guo et al., 2005; Polishchuk et al., 2014; Schaefer et al., 1999) to
facilitate copper excretion into the bile. The C-terminus has an
important role in regulating copper-responsive trafficking.
Mutations of residues in this region are suggested to contribute to
aberrant Golgi retention of ATP7B in high-copper circumstances
(Braiterman et al., 2011). Our fluorescence studies did not show a
significant difference in GFP signals in both HeLa and polarized
HepG2 cells between the wild type and ATP7BR1415Q after copper
treatment. However, ATP7BR1415Q showed increased retention in
the ER and failure to reach the canalicular surface in polarized
hepatic cells in high-copper conditions, which might occur because
of mis-folding of the protein. Mis-folding and aberrant retention in
the ER have been previously reported in Wilson disease-associated
ATP7B mutations (Gupta et al., 2011; van den Berghe et al., 2009).
The luciferase assay demonstrated that the copper-transport capacity
of ATP7BR1415Q showed only a modest impairment, indicating that
the functional effect of ATP7BR1415Q in hepatic copper
accumulation in Labrador retrievers results from mis-localization
of the protein, rather than from severely decreased copper-transport
capacity.
In Labrador retrievers, there is a strong female predisposition for
disease (Fieten et al., 2012b). X-chromosomal mapping in a
combined data set can be hampered by hemizygosity in males,
and thereby, possibly cause disturbance of association signals.
Therefore, we analysed males and females separately. In the region
harbouring ATP7A, we identified a suggestive signal of association
with lower hepatic copper levels in male dogs.We hypothesized that
mutations in ATP7A might modify copper accumulation, and this
gene was therefore analysed by DNA sequence analysis. The
identified missense mutation ATP7A:c.980C>T results in the amino
acid substitution ATP7A:p.Thr327Ile in MBD3 of ATP7A and was
negatively associated with hepatic copper levels. MBD3 is located
in the cytoplasm and has the ability to receive copper from the
Atox1 chaperone (Strausak et al., 2003). MBD3 of ATP7A is only
metallated in elevated copper conditions (Banci et al., 2010) and is
thought to be an important domain for regulating ATP7A activity
via cell-signalling pathways (Veldhuis et al., 2011). It has been
shown that ATP7A:p.T327 is an important phosphorylation site of
ATP7A (Veldhuis et al., 2009).
To investigate whether ATP7AT327I influenced cellular copper
accumulation, we studied copper uptake and retention in dermal
fibroblasts derived from Labrador retrievers hemi- or homozygous
for either ATP7AWT or ATP7AT327I. Mutant fibroblasts
accumulated significantly more copper and showed a decreased
efflux ratewithout a change in protein expression levels, indicating a
functional impairment of ATP7A.We also investigated whether this
could be a result of aberrant trafficking or sorting of the mutant upon
copper stimulation. Hereto, we used wild-type and ATP7AT327I
dermal fibroblasts and polarized MDCKs transfected with either
ATP7AWT or ATP7AT327I. In both experiments, correct trafficking
to the plasma membrane and delivery to the basolateral membrane
(in polarized MDCKs) upon copper stimulation was observed.
These results are in line with previous observations that the
phosphorylation site ATP7A:pT327 is not involved in aberrant
trafficking of ATP7A (Veldhuis et al., 2009), but is rather predicted
to stabilize a conformational change in ATP7A, exposing the CxxC
copper-binding region of MBD3, which might affect catalytic
activity of ATP7A (Veldhuis et al., 2011). This might indicate that
catalytic activity, rather than aberrant trafficking of ATP7A, is
responsible for the observed decrease in hepatic copper levels in
Labrador retrievers.
In humans, disease-causing mutations in the third metal-binding
domain of ATP7Awere not reported (Kaler, 2011). For ATP7B, 15
(three silent, 12 Wilson disease-causing) variants in MBD3 are
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described. Two mutations, c.915T>A (Loudianos et al., 1998) and
c.918-931del (Davies et al., 2008), lead to a premature stop and a
concomitant absence of ATP7B:p.Ser306 (corresponding to
ATP7A:p.Thr327). Both of these mutations cause Wilson disease.
Another single base-pair substitution, C>T, located in intron 18
(position 60338569, CF 3.1), was also inversely related to hepatic
copper score. In the dogs fromwhich the fibroblasts were derived, the
SNP in intron 18 and ATP7A:c.980C>T were in complete LD, and
therefore we cannot rule out the possibility that the intronic variation
exerts an effect onATP7A gene function; however, we consider it less
likely. The alleles are both pyrimidines within a stretch of
pyrimidines, are not situated close to an intron-exon junction, and
the mutation is not expected to activate a cryptic splice site. In the
total data set, the intronic SNPwas in high LD (r2 0.92, D′ 0.97) with
ATP7A:c.980C>T, making it likely that the observed association is a
result of the fact that this SNP is in LD with ATP7A:c.980C>T.
ATP7B:c.4358G>A showed an additive effect on hepatic copper
levels, which was most significant in female dogs (Fig. 2). Copper-
accumulating effects of ATP7B:c.4358G>A were modified by the
presence of ATP7A:c.980C>T, and this effect was most clear in
male dogs (Table 2). In accordance with observations in humans
with Menkes disease, where aberrant ATP7A function results in an
impaired intestinal copper uptake, we suggest that in Labrador
retrievers ATP7AT327I might result in decreased intestinal copper
uptake, thereby attenuating hepatic copper accumulation because of
ATP7BR1453Q. Other possible mechanisms influencing copper
homeostasis in Labrador retrievers and, more specifically, the
interplay between ATP7A and ATP7B might include regulation by
hormones, inflammatory cytokines, growth factors or a yet
unidentified small molecule acting as a regulator of systemic
copper metabolism (Kim et al., 2010).
In humans with Wilson disease, a wide variation in clinical
symptoms and hepatic copper accumulation is noticed, which is
currently unexplained (de Bie et al., 2007; Lee et al., 2011; Riordan
and Williams, 2001; Shah et al., 1997). When we translate our
observations in the Labrador retrievers to the human disease, we
might think of ATP7A as a possible modifier gene inWilson disease.
Variations in ATP7A with a small effect on protein function might
reduce the rate of copper accumulation in humans with Wilson
disease, thereby modifying the disease phenotype, for example by
delaying the age at onset of clinical symptoms. In fact, part of the
apparent discrepancy between the genetic incidence of Wilson
disease and the number of affected individuals diagnosed (Coffey
et al., 2013) might be a result of a slower rate of copper
accumulation that does not reach toxic levels in the life span of
some individuals. In a recent pilot study, two SNPs in ATP7Awere
genotyped in humans with Wilson disease. No association was
identified between the ATP7A polymorphisms and the presence of
Wilson disease or clinical phenotypic parameters (Przybyłkowski
et al., 2014). However, these results clearly do not exclude ATP7A
as a candidate modifier, because it was a very limited investigation
of ATP7A and a small data set.
In conclusion, the present study illustrates the potential of canine
inbred populations for the unravelling of complex hereditary
diseases. We identified the involvement of the copper transporter
ATP7B in copper toxicosis in the Labrador retriever, identifying this
breed as the first naturally occurring non-rodent mammalian model
for Wilson disease. The concurrent identification of a functional
mutation in ATP7A suggests a role for the Menkes gene as a disease
modifier in copper-metabolism disorders. Owing to its long life
span and large body size, the Labrador retriever will be an
invaluable large-animal model for the development of new




Samples for the initial GWAS and DNA sequencing study were collected
between 2003 and 2009, and samples for the replication cohort were
collected between 2009 and 2013 at the Faculty of Veterinary Medicine,
Utrecht University, with informed consent of the owners. The procedures
were approved by the Utrecht University Ethical Committee as required
under Dutch legislation. In addition, procedures were reviewed and
approved by the WALTHAM Centre for Pet Nutrition. Each dog
underwent a physical examination. An EDTA blood sample of 4 ml was
used for DNA extraction from peripheral white blood cells by a salt
extraction procedure (Miller et al., 1988). For diagnostic purposes, liver
biopsies were obtained by theMenghini technique, ultrasound guided with a
Tru-cut device and 14 gauge needle, during laparoscopy or laparotomy
(Rothuizen et al., 2006). Local anaesthetics (infiltration of the skin and
subcutaneous tissues with lidocaine) were applied for Tru-cut liver biopsies.
When necessary, dogs were sedated with propofol (dosage to effect) during
the liver biopsy procedure. For liver biopsies obtained by laparoscopy or
laparotomy, dogs underwent general anaesthesia. The anaesthesia protocols
used were individually designed based on the anaesthetic risk classification
of the American Association of Anesthesiologists. Tissue specimens were
embedded in paraffin, and 4 µm thick sections were mounted on glass slides.
Sections were stained with haematoxylin and eosin, rubeanic acid (Uzman,
1956) for copper and reticulin (Gordon and Sweets, 1936). All samples were
evaluated and graded by one board-certified pathologist (T.S.G.A.M.v.d.I.)
according to World Small Animal Veterinary Association standards (Van
Den Ingh et al., 2006). Hepatic copper accumulation was histologically
graded on a scale from zero to five as described previously (Fieten and
Rothuizen, 2014).
Electron microscopy
For routine electron microscopic analysis, liver specimens were obtained
from two Labrador retrievers affected with copper toxicosis and one healthy
dog of mixed breed. Biopsies were fixed in 1% glutaraldehyde in 0.2 M
HEPES buffer. Small blocks of liver tissue were post-fixed in uranyl acetate
and in OsO4. After dehydration through a graded series of ethanol, the tissue
samples were cleared in propylene oxide, embedded in the Epoxy resin
(Epon 812) and polymerized at 60°C for 72 h. From each sample, thin
sections were cut with a Leica EMUC7 ultra-microtome. Thin sections were
investigated further using a FEI Tecnai-12 (FEI; Eindhoven, The
Netherlands) electron microscope equipped with a Veletta CCD camera
for digital image acquisition.
Genome-wide association study
DNA samples from 235 Labrador retrievers were genotyped using
Illumina’s Canine HD BeadChip, containing ∼170,000 SNPs. Data were
analysed in the R-package (R Development Core Team, 2011) ‘GenABEL’
version 1.6-6 (Aulchenko et al., 2007). Quality-control thresholds were set
using the function ‘check.marker’. A threshold of 98% successful genotypes
per individual and 98% successful genotypes per SNP was used. SNPs for
which at least 20 heterozygotes were typed were included in the analysis.
Furthermore, a check for sex mismatch (based on genotypes at the X
chromosome), duplicate sample checks and checks for heterozygosity
outliers were performed. The phenotype copper score was analysed as a
quantitative trait, and sex was modelled as a fixed factor. Stratification and
cryptic relatedness were adjusted for by mixed models implemented in the
function ‘mmscore’ (Chen and Abecasis, 2007). A correction for residual
genomic control was applied. The heritability of hepatic copper score with
correction for sex was calculated based on genotype kinship matrix with the
function ‘polygenic_hglm’ based on the packages ‘hglm’ (Ronnegard et al.,
2010) and ‘GenABEL’. The autosomes and pseudo-autosomal region of the
X chromosome were analysed in male and female dogs together. An
additional stratified analysis for males and females was performed to
facilitate inspection of the X chromosome.
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Genome-wide suggestive association criteria were set to an uncorrected
P-value of P≤5×10−5. Boundaries for the crucial intervals were determined
for a significance level of P≤5×10−4. Crucial intervals were screened for the
presence of possible candidate genes.
DNA sequence analysis and validation
Exons and intron-exon boundaries from positional candidate genes were
selected for Sanger sequencing in 96 individual dogs randomly selected
from the 235 Labrador retrievers used in the initial GWAS. Variants that
were significantly associated with hepatic copper level were genotyped in an
independent replication cohort of 59 Labrador retrievers and in all 294 dogs.
Statistical analysis was performed with R version 2.11 (R Development
Core Team, 2011). A linear regression model with sex as a covariate was
used to test the association of the mutations identified with Sanger
sequencing in the candidate genes with hepatic copper score. The mutations
were modelled in an additive way.
Genotypes for the mutations that were significant after statistical testing in
the replication cohort were genotyped by Sanger sequencing in the total
cohort of 294 dogs. Differences in hepatic copper scores with respect to
combined ATP7A and ATP7B genotype were determined using a Wilcoxon
rank-sum test within males and females separately.
Genotypes for ATP7B:c.4358G>A and ATP7A:c.980C>T were added as
independent covariates, and heritability was calculated by using the function
‘polygenic_hglm’ (Ronnegard et al., 2010) in GenABEL. The explained
genetic variability was calculated by the following formula: (heritability of
model without mutations as a covariate minus heritability including
mutations as covariates/heritability without mutations as a covariate). In
all heritability calculations, sex was added as a covariate.
Functional evaluation of ATP7BR1453Q
Alignment of human and canine ATP7B protein sequence confirmed that
the Arg at position 1453 in the canine protein corresponds to the Arg at
position 1415 in the human ATP7B. The human pAdlox-ATP7B-GFP
construct was used, and site-directed mutagenesis was performed to make
pAdloxATP7B-p:Arg1415Gln-GFP. Both constructs were used for cell
transfection and subsequent immunofluorescence and luciferase assays.
DNAs and site-directed mutagenesis
To prepare ATP7B:p.Arg1415Gln, the pAdlox-ATP7B-GFP construct
(provided by S. Lutsenko, Baltimore, MD, USA) was used as the
template, and site-directed mutagenesis was performed according to the
manufacturer’s instructions for point mutagenesis using the QuikChange II
XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA), using the
following oligonucleotides: 5′-GGGACTCCCCCCAGGCCACACCATG-
GGACC-3′ and 5′-GGTCCCATGGTGTGGCCTGGGGGGAGTCCC-3′.
Given that ATP7A sequences are unstable in high-copy plasmids
(reference PMID: 9571140), we used commercial DNA synthesis to
generate silent mutations in the mouse Atp7a open reading frame in the hope
that such changes would permit stable propagation in high-copy plasmids.
Overlapping PCR was used to generate more than 1000 silent mutations
within the mouse Atp7a open reading frame (Life Technologies, Grand
Island, NY). Two synthetic DNA fragments were generated. The first was a
2.0 kb fragment flanked by AccIII/XbaI restriction sites, and the second was
a 1.2 kb fragment flanked by XbaI/XhoI restriction sites. Each was
subcloned in the high-copy pMK-RQ vector, and at least three clones
were sequenced and found to lack new mutations, indicating that both
fragments were stably propagated in Escherichia coli. A third DNA
fragment that encompassed the last 1.4 kb of the native mouse Atp7a open
reading frame was generated by PCR using primers 5′-ACCATCTAGAC-
TCGAGATGGCTCATAAGGTAAAGGTAGTGGTATTTGATAAGAC-
TGG and 5′-AGATGCGGCCGCTTACAGTGTGGTGTCATCATCTTC-
CCGGAAGTCG. A complete Atp7a construct was then generated by
ligations involving this PCR product and both synthetic fragments, and
subcloned into the expression construct, pQCXIP (Clontech). The resulting
Atp7a expression plasmid was found to be stably propagated in E. coli and
verified by sequence analysis. A PCR fragment containing the EGFP
sequence flanked by MfeI sites was appended to the 5′ region of Atp7a to
generate the pAtp7a-GFP plasmid. GFP-tagged ATP7AT327I mutant was
generated using standard mutagenesis service by GenScript.
Reagents
Antibodies were obtained from the following sources: anti-ATP7A (Hycult
Biotech, Plymouth Meeting, PA, USA), anti-Human Golgin-97 Mouse
Monoclonal CDF4 (Molecular Probes, Paisley, UK), anti-GFP and anti-
VAP-A from M.A. De Matteis (TIGEM, Naples, Italy), anti-α-tubulin
(Sigma-Aldrich, St Louis, MO, USA), anti-TGN46 (AbD Serotec, Oxford,
UK); anti-Na+/K+-ATPase (Abcam, Cambridge, UK), anti-MRP2 (Enzo
Life Sciences, Lausanne, Switzerland), anti-occludin and secondary Alexa
Fluor 568-conjugated antibodies (Invitrogen-Life Technologies, Grand
Island, NY, USA). Dual-Luciferase® reporter assay kit was from Promega
(Madison, WI, USA).
Cells and transfection
Hela and HepG2 cells were routinely grown at 37°C in Dulbecco’s modified
Eagle’s medium (DMEM), containing 10% FBS (fetal bovine serum with
inactivated complement for HepG2) on coverslips and transfected with
pAdlox-ATP7B-GFP, pAdlox-ATP7B-H1069Q-GFP and pAdlox-ATP7B-
R1415Q-GFP using TransIT®-LT1 and jetPEI® polyplus transfection
protocols for Hela and HepG2, respectively, according to the
manufacturer’s instructions. ATP7B-H1069Q was used as a control
because it is one of the most common Wilson disease mutations in the
Caucasian population and impairs ATP7B function. To reach polarization,
HepG2 cells were grown according to the published protocol for 72 h
(Slimane et al., 2003).
MDCK cells were grown on Transwell polycarbonate filters (Corning
Costar, Lowell, MA, USA) in DMEM containing 10% FBS for 4-5 days to
achieve sufficient polarization. GFP-tagged ATP7A-WT or ATP7B-T327I
were transfected using TransIT®-LT1 2 days before the experiment.
Luciferase assay
For the luciferase assay, the pAdloxATP7B-H1069Q-GFP construct was
used as a positive control, because ATP7B-H1069Q is the most common
mutation causing Wilson disease in the Caucasian population and proved to
be functionally active. HeLa cells were plated in a 12-well plate and
transfected with pGL3-E1b-TATA-4MRE reporter (van den Berghe et al.,
2007; provided by Bart van de Sluis, Groningen, The Netherlands) and then
co-transfected with either empty vector (pEGFPc1) or pAdloxATP7B-GFP
or pAdloxATP7B-H1069Q-GFP or pAdloxATP7B-p:Arg1415Gln-GFP
expression plasmids using the TransIT®-LT1 transfection protocol. After
24 h, cells were treated with 200 μM CuSO4 for 24 h. Cells were
subsequently harvested in a Passive Lysis Buffer (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. Firefly luciferase and
Renilla luciferase activities were measured with a Dual-Luciferase® reporter
assay system (Promega) on a GloMax® 96 Microplate Luminometer
(Promega) according to the manufacturer’s instructions. Relative light units
were calculated by dividing firefly measurements by Renillameasurements.
All values were normalized to the ATP7B protein expression levels
determined by ImageJ (Collins, 2007) analysis of western blot in the
respective specimens. Western blot analysis was performed on lysates
obtained by transfection of the cells with pEGFP-C1, pAdlox-ATP7B-GFP,
pAdlox-ATP7B-H1069Q-GFP and pAdlox-ATP7B-:Arg1415Gln-GFP
expression plasmids. Lysates were prepared via the addition of lysis
buffer [0.5% Triton X-100, 20 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA (pH 8), 0.5% Np-40, 10% glycerol and 1× protease inhibitor
cocktail (Sigma S88201)] for 10 min at room temperature. The mixture was
placed into amicrofuge tube, kept on ice for 10 min, and then spun at 17,000 g
for 15 min at 4°C in a microcentrifuge. The quality of transfer was verified by
Ponceau staining, and molecular weights were inferred by comparison to
prestained markers (New England Biolabs, Ipswich, MA, USA).
Functional evaluation of ATP7AT327I
Dermal fibroblast cells were derived from Labrador retrievers selected for
the presence or absence of an ATP7A:c.980C>T substitution resulting in the
ATP7AT327I amino acid substitution in homozygous or hemizygous form.
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The human dermal fibroblast cells HB156 from an individual with clinical
Menkes disease (cell line: DD0355, no. 91071704) were purchased from the
European Collection of Cell Cultures (ECACC). ECACC is managed as part
of the Health and Safety Executive (HSE) in the UK. The human HDFn
dermal fibroblast line (Invitrogen, Bleiswijk, The Netherlands) was used as
a control cell line.
Fibroblast cultures were routinely maintained in DMEM (Invitrogen)
supplemented with L-glutamine (2 mM), 10% FBS, MEM non-essential
amino acids (100 µM) and penicillin-streptomycin at 37°C in a humidified
atmosphere of 5% CO2 in air. For experiments, canine cells were used
between passage 4 and 9.
Radioisotope experiments
Methods for radioisotope experiments were based on those described
previously (Spee et al., 2007). In short, 64Cu was prepared using metallic
copper wire (1 mg) irradiated overnight to provide an induced activity of
approximately 16.6 Ci/g (Reactor Institute, Delft, The Netherlands). Four
hours after irradiation and 30 min before the start of the study, the copper
wire was dissolved in 100 µl 10.3 M HNO3 and subsequently neutralized
with 0.5 M NaOH. DMEM was added to give a final concentration of
10 mM copper. Fibroblasts were cultured from skin-punch biopsies,
obtained with local anaesthesia (lidocaine infiltration).
Fibroblast cells were plated in triplicate in six-well plates in DMEM+10%
FBS. Cells were incubated with 3 µM 64Cu for 6, 22 or 30 h. Culture
medium was removed after treatment, and the cells were washed four times
with Hanks solution containing 3 µM CuCl2. Following wash steps, 325 µl
of 0.2% SDS was added to lyse the cells. Cellular copper loading was
determined from counts of the cell lysate (450 and 800 keV for 1 min;
Packard B5003 gamma counter; Packard BioScience Benelux, Groningen,
The Netherlands). For efflux studies, after copper treatment for 22 h as
described above, cells were washed four times with Hanks solution
containing 3 µM CuCl2 before incubation in fresh medium containing no
additional copper for 8 h. Cellular copper loading was assessed at 0, 0.5, 1.5,
3, 6 and 8 h as described in the previous paragraph. Copper loading was
normalized to the protein concentration of the cell lysate (Bio-Rad Protein
Assay Kit; Bio-Rad, The Netherlands). 65Zn (PerkinElmer; 1 mCi chloride
solution) was used as a control and prepared as described for 64Cu
experiments. The use of canine and human fibroblasts was approved by the
Utrecht University Ethical Committee and the WALTHAM Centre for Pet
Nutrition.
Statistical analysis
Counts per minute normalized to the protein concentration of the cell
lysate (in counts per minute per milligram) were analysed using linear
mixed-effect modelling with the R package ‘nlme’. The outcome variable
was transformed by taking its natural logarithm in order to fulfil the
criteria of normality and constant variance of residuals. Restricted
maximum likelihood was used to estimate the fixed effects of duration
of 64Cu treatment (in hours, modelled as a categorical factor), presence or
absence of the ATP7A:p.Thr327Ile substitution, sex (male, female) and
their interactions. A stepwise backward method was used to determine the
model of best fit, based on Akaike’s information criterion. Estimates were
reported with their 95% confidence intervals. For the efflux studies, the
amount of 64Cu at the start of the experiment was set to 100%, and at the
time points 0.5, 1.5, 3, 6 and 8 h the amount of 64Cu was calculated as a
percentage of the initial value. Per time interval, the efflux rate of copper
out of the cells was calculated as the percentage efflux per hour. The
average efflux rates of fibroblasts derived from dogs with ATP7A wild
type and dogs with the ATP7A:p.Thr327Ile substitution were compared
using Student’s unpaired t-test.
Western blot
Fibroblasts were treated with 3 µM copper for 0, 6, 22 or 30 h before
harvesting. Cell lysates were heated to 70°C for 5 min in loading buffer
[50 mM Tris-HCl (pH 6.8), 2% SDS, 0.1% bromophenol blue, 10%
glycerol and 40 mM dithiothreitol] and loaded onto preassembled
SDS-PAGE. The membrane was blocked with ECL blocking for 1 h,
before overnight incubation at 4°C with chicken IgY anti-ATP7A (no.
13995; Abcam) at a dilution of 1:2000 followed by a 1 h incubation at room
temperaturewith the secondary antibody horseradish peroxidase-conjugated
goat anti-chicken (no. ab6877; Abcam) at a dilution of 1:40,000 in blocking
buffer. In order to show equal protein loading, membranes were western
blotted with rabbit anti-tubulin (no. ab6046; Abcam; 1:10,000 dilution)
followed by goat anti-rabbit horseradish peroxidase (no. sc2004; Santa
Cruz; 1:20,000) and visualized with ECL western blotting detection
reagents.
Immunofluorescence
The intracellular distribution of GFP-tagged ATP7B or ATP7A proteins
was observed 24 or 48 h after transfection. Cells were treated with
500 µM BCS overnight and fixed directly or washed and incubated for
2 h with 200 µM CuSO4 before fixation in 4% paraformaldehyde. Then
the cells were incubated with blocking/permeabilizing solution (0.5%
bovine serum albumin, 0.1% saponin and 50 mM NH
4
Cl in PBS) for
20-30 min. Primary and secondary antibodies were diluted in blocking/
permeabilizing solution and added to the cells overnight and for 45 min,
respectively. Co-localization between ATP7B variants and organelle
markers was visualized using anti-TGN46 antibody (Golgi marker),
VAP-A antibody (ER marker), Na+/K+-ATPase antibody (plasma
membrane marker) and LAMP1 antibody (late endosome/lysosome
marker) followed by the Alexa Fluor 568 secondary antibody.
Antibodies against the tight junction protein occludin were used to
label the border between apical and basolateral domains in MDCK cells.
To visualize canalicular domains, polarized HepG2 cells expressing
ATP7BWT or ATP7BR1415Q were labelled with anti-MRP2 antibody
followed by the secondary anti-mouse Alexa Fluor 568. Canine dermal
fibroblasts were treated with BCS or CuSO4 as described above, fixed
and stained for endogenous ATP7A with anti-ATP7A antibodies and
with anti-Golgin97 to reveal TGN46. The images were acquired using a
63×1.4 NA oil immersion objective at an LSM710 or LSM700 confocal
microscope with appropriate filter sets (Carl Zeiss, Jena, Germany). The
intracellular distribution of GFP-tagged ATP7B protein was analysed in
10 randomly selected fields, and the percentage of the cells exhibiting
ATP7B in ER, Golgi and/or plasma membrane/vesicles was quantified.
A Wilcoxon rank-sum test was used to test differences in percentages of
GFP positivity within the ER, Golgi and/or plasma membrane. A P-
value <0.05 was considered significant. For polarized MDCK cells,
confocal z-stacks through the entire cell monolayer were taken, and xz
sections were generated using Zeiss Zen software.
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